CNS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized
| CNS PHARMACEUTICALS, INC. | ||
| Date: March 31, 2025 | By: | /s/ John Climaco |
|---|---|---|
| John Climaco | ||
| Chief Executive Officer and Director (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.
| Date: March 31, 2025 | By: | /s/ John Climaco |
|---|---|---|
| John Climaco | ||
| Chief Executive Officer, President and Director (Principal Executive Officer) | ||
| Date: March 31, 2025 | /s/ Christopher Downs |
|---|---|
| Christopher Downs | |
| Chief Financial Officer (Principal Financial and Accounting Officer) |
| Date: March 31, 2025 | /s/ Faith Charles |
|---|---|
| Faith Charles | |
| Director |
| Date: March 31, 2025 | /s/ Jerzy (George) Gumulka |
|---|---|
| Jerzy (George) Gumulka | |
| Director | |
| Date: March 31, 2025 | /s/ Jeffry Keyes |
| Jeffry Keyes | |
| Director | |
| Date: March 31, 2025 | /s/ Bettina Cockroft |
| Bettina Cockroft | |
| Director |
| Date: March 31, 2025 | /s/ Amy Mahery |
|---|---|
| Amy Mahery | |
| Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.